Related Experiment Video
Updated: Mar 5, 2026

10:52
Closure of a Patent Foramen Ovale PFO: An Intervention Sequence
Published on: December 23, 2022
6.5K
Patent ductus arteriosus and pulmonary arterial hypertension: Is it closer to closure?
Dhaval Parekh1, Zvonimir Krajcer1
1Department of Cardiology, Texas Heart Institute, Houston, Texas.
Abstract
No abstract available in PubMed .
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
737
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
737
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
517
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
517

